Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

This study has been terminated.
(The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The use mothod of 250mg per month in clinical practice is off-label.)
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01425294
First received: August 19, 2011
Last updated: April 4, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)